These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33131335)

  • 1. An overview of disease models for NLRP3 inflammasome over-activation.
    Zhang H; Zahid A; Ismail H; Tang Y; Jin T; Tao J
    Expert Opin Drug Discov; 2021 Apr; 16(4):429-446. PubMed ID: 33131335
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases.
    Zhang X; Xu A; Lv J; Zhang Q; Ran Y; Wei C; Wu J
    Eur J Med Chem; 2020 Jan; 185():111822. PubMed ID: 31699536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential.
    Su M; Wang W; Liu F; Li H
    Curr Med Chem; 2021; 28(3):569-582. PubMed ID: 31971103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases.
    Jiang H; Gong T; Zhou R
    Adv Immunol; 2020; 145():55-93. PubMed ID: 32081200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of terpenoids as inflammasome inhibitors.
    Hortelano S; González-Cofrade L; Cuadrado I; de Las Heras B
    Biochem Pharmacol; 2020 Feb; 172():113739. PubMed ID: 31786260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NLRP3 inflammasome in ischemic stroke: As possible therapeutic target.
    Alishahi M; Farzaneh M; Ghaedrahmati F; Nejabatdoust A; Sarkaki A; Khoshnam SE
    Int J Stroke; 2019 Aug; 14(6):574-591. PubMed ID: 30940045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
    Han X; Sun S; Sun Y; Song Q; Zhu J; Song N; Chen M; Sun T; Xia M; Ding J; Lu M; Yao H; Hu G
    Autophagy; 2019 Nov; 15(11):1860-1881. PubMed ID: 30966861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors.
    Zhao N; Li CC; Di B; Xu LL
    J Autoimmun; 2020 Sep; 113():102515. PubMed ID: 32703754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NLRP3 inflammasome: a therapeutic target for inflammation-associated cancers.
    Gouravani M; Khalili N; Razi S; Keshavarz-Fathi M; Khalili N; Rezaei N
    Expert Rev Clin Immunol; 2020 Feb; 16(2):175-187. PubMed ID: 31928260
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases.
    Seok JK; Kang HC; Cho YY; Lee HS; Lee JY
    Arch Pharm Res; 2021 Jan; 44(1):16-35. PubMed ID: 33534121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases.
    Vong CT; Tseng HHL; Yao P; Yu H; Wang S; Zhong Z; Wang Y
    Drug Discov Today; 2021 Jun; 26(6):1394-1408. PubMed ID: 33636340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases.
    Jahan S; Kumar D; Chaturvedi S; Rashid M; Wahajuddin M; Khan YA; Goyal SN; Patil CR; Mohanraj R; Subramanya S; Ojha S
    Curr Med Chem; 2017; 24(16):1645-1670. PubMed ID: 28245768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paricalcitol attenuates TGF-β1-induced phenotype transition of human peritoneal mesothelial cells (HPMCs) via modulation of oxidative stress and NLRP3 inflammasome.
    Ko J; Kang HJ; Kim DA; Ryu ES; Yu M; Lee H; Lee HK; Ryu HM; Park SH; Kim YL; Kang DH
    FASEB J; 2019 Feb; 33(2):3035-3050. PubMed ID: 30354670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttranslational Regulation of the NLR Family Pyrin Domain-Containing 3 Inflammasome.
    Shim DW; Lee KH
    Front Immunol; 2018; 9():1054. PubMed ID: 29868015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space.
    Schwaid AG; Spencer KB
    J Med Chem; 2021 Jan; 64(1):101-122. PubMed ID: 33351619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NEK7: a potential therapy target for NLRP3-related diseases.
    Liu G; Chen X; Wang Q; Yuan L
    Biosci Trends; 2020 May; 14(2):74-82. PubMed ID: 32295992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay Between NLRP3 Inflammasome and Autophagy.
    Biasizzo M; Kopitar-Jerala N
    Front Immunol; 2020; 11():591803. PubMed ID: 33163006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NLRP3 Inflammasome as a Pharmacological Target.
    Marchetti C
    J Cardiovasc Pharmacol; 2019 Oct; 74(4):285-296. PubMed ID: 31335445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NLRP3 inflammasome: A likely target for the treatment of allergic diseases.
    Xiao Y; Xu W; Su W
    Clin Exp Allergy; 2018 Sep; 48(9):1080-1091. PubMed ID: 29900602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.
    Shao A; Wu H; Hong Y; Tu S; Sun X; Wu Q; Zhao Q; Zhang J; Sheng J
    Mol Neurobiol; 2016 Jul; 53(5):3462-3476. PubMed ID: 26091790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.